82 related articles for article (PubMed ID: 18281654)
1. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
2. Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
Šimánek V; Vrzáková R; Viták R; Jirásko M; Fürst T; Topolčan O; Pecen L; Vurm V; Kučera R
Prostate; 2024 May; 84(7):656-665. PubMed ID: 38414098
[TBL] [Abstract][Full Text] [Related]
3. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
4. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
[TBL] [Abstract][Full Text] [Related]
5. Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratio.
Ferraro S; Biganzoli D; Rossi RS; Palmisano F; Bussetti M; Verzotti E; Gregori A; Bianchi F; Maggioni M; Ceriotti F; Cereda C; Zuccotti G; Kavsak P; Plebani M; Marano G; Biganzoli EM
Clin Chem Lab Med; 2023 Jun; 61(7):1327-1334. PubMed ID: 36704961
[TBL] [Abstract][Full Text] [Related]
6. Associations of the Geriatric Nutritional Risk Index with high risk for prostate cancer: A cross-sectional study.
Miao S; Bao C; Zhang Y; Wang L; Jin X; Huang B; Zhang Z; Wang W
Nutrition; 2023 Nov; 115():112164. PubMed ID: 37573791
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the diagnostic accuracy of prostate specific antigen.
Harvey P; Basuita A; Endersby D; Curtis B; Iacovidou A; Walker M
BMC Urol; 2009 Sep; 9():14. PubMed ID: 19744336
[TBL] [Abstract][Full Text] [Related]
8. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.
Shariat SF; Canto EI; Kattan MW; Slawin KM
Rev Urol; 2004; 6(2):58-72. PubMed ID: 16985579
[TBL] [Abstract][Full Text] [Related]
9. Retracted: Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9839167. PubMed ID: 38094390
[TBL] [Abstract][Full Text] [Related]
10. [
Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
[TBL] [Abstract][Full Text] [Related]
11. Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Burns RB; Olumi AF; Owens DK; Smetana GW
Ann Intern Med; 2019 Jun; 170(11):770-778. PubMed ID: 31158876
[TBL] [Abstract][Full Text] [Related]
12. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
13. Delayed response after repeated
Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
[TBL] [Abstract][Full Text] [Related]
14. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed HU; El-Shater Bosaily A; Brown LC; Gabe R; Kaplan R; Parmar MK; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham AP; Oldroyd R; Parker C; Emberton M;
Lancet; 2017 Feb; 389(10071):815-822. PubMed ID: 28110982
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
17. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Lilja H; Ulmert D; Vickers AJ
Nat Rev Cancer; 2008 Apr; 8(4):268-78. PubMed ID: 18337732
[TBL] [Abstract][Full Text] [Related]
19. An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.
Inman BA; Zhang J; Shah ND; Denton BT
BJU Int; 2012 Aug; 110(3):375-81. PubMed ID: 22313933
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in prostate cancer I: blood-based markers.
Shariat SF; Semjonow A; Lilja H; Savage C; Vickers AJ; Bjartell A
Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):61-75. PubMed ID: 21604943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
